How many insider trades does FilingIQ track for AVBP?

FilingIQ tracks 35 Form 4 insider transactions for AVBP (ArriVent BioPharma, Inc.), covering filings from Jan 30, 2024 onwards. 4 of those were filed in the last 90 days.

Are AVBP insiders net buyers or net sellers?

Across the full Form 4 history for AVBP, 6 transactions (17%) were open-market purchases and 1 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does AVBP insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is AVBP in?

ArriVent BioPharma, Inc. (AVBP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $936.05M.

AVBP insider trading

Healthcare

ArriVent BioPharma, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

17% / 3%

Market cap

$936.05M

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Company website: arrivent.com

AVBP insider activity at a glance

FilingIQ has scored 35 insider transactions for AVBP since Jan 30, 2024. The most recent filing in our index is dated Jun 18, 2026.

Across the full history, 6 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on AVBP insider trades is 57.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live AVBP trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,196

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

First Tracks Biotherapeutics, Inc.

NTRA 133

Natera, Inc.

Frequently asked

How many insider trades does FilingIQ track for AVBP?: FilingIQ tracks 35 Form 4 insider transactions for AVBP (ArriVent BioPharma, Inc.), covering filings from Jan 30, 2024 onwards. 4 of those were filed in the last 90 days.
Are AVBP insiders net buyers or net sellers?: Across the full Form 4 history for AVBP, 6 transactions (17%) were open-market purchases and 1 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AVBP insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is AVBP in?: ArriVent BioPharma, Inc. (AVBP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $936.05M.

Methodology & sources

Every AVBP insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.